March 4, 2008 — The safety labeling for oseltamivir phosphate ( Tamiflu, Roche Laboratories Inc) has been revised to include stronger warnings regarding the risk for neuropsychiatric adverse events, the US Food and Drug Administration (FDA) warned healthcare professionals today. The revisions were the result of recommendations made by the agency's Pediatric Advisory Committee meeting held in November 2007. GlaxoSmithKline Plc has also added a warning to the label of zanamivir (Relenza) for neuropsychiatric adverse events, as reported by Reuters Health. Symptoms of delirium and abnormal behavior leading to sometimes fatal self-injury have been reported with use of oseltamivir for the treatment of influenza, primarily in Japan, according to an alert issued by MedWatch, the FDA's safety information and adverse event reporting program. These events occurred primarily among pediatric patients and were often abrupt in onset and resolution.